Company: CDT
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001641172-25-023191
Chunk: 22

Company: CDT Equity Inc.
Filing Date: 2025-08-12
Form: 424B3
Chunk 22
---
 or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

Our Common Stock is listed on The Nasdaq Capital Market under the symbol “CDT”.

| 16 |

<div align='center'>LEGAL MATTERS</div>

The validity of the securities being offered by this prospectus will be passed upon for us by Thompson Hine LLP, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated financial statements of CDT Equity Inc. as of and for the years ended December 31, 2024 and 2023, incorporated by reference in this prospectus and registration statement of which this prospectus is a part have been audited by Marcum LLP (now part of CBIZ CPAs P.C.), an independent registered public accounting firm, as stated in its report thereon, and which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, and are included in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.

<div align='center'>WHERE YOU CAN FIND ADDITIONAL INFORMATION</div>

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is www.sec.gov.

Copies of certain information filed by us with the SEC are also available on our website at www.conduitpharma.com. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus or any prospectus supplement. Our website address is included in this prospectus as an inactive textual reference